Aadi Bioscience Earnings Reports

Aadi Bioscience reported FYARRO sales of $7.2 million for Q3 2024, reflecting a 21% year-over-year increase. The company is actively engaged in a comprehensive strategic review to maximize shareholder value and expects current resources to fund operations into at least 2H 2026.

Aadi Bioscience reported FYARRO sales of $6.2 million for Q2 2024, a 15% increase quarter-over-quarter. The company is progressing with its PRECISION1 trial and expects an interim analysis in Q3 2024. Net loss for the quarter was $14.6 million.

Aadi Bioscience reported total revenue of $5.4 million for Q1 2024, primarily from FYARRO sales. The company experienced a net loss of $18.3 million. Key developments include the full enrollment of the PRECISION1 trial and ongoing enrollment in Phase 2 trials for EEC and NETs.

Aadi Bioscience reported Q4 2023 revenue of $6.3 million from FYARRO sales, a 21% increase year-over-year. The company's net loss for the quarter was $16.3 million. They are on track with their PRECISION1 trial and initiated enrollment in two Phase 2 trials.

Aadi Bioscience announced its Q2 2023 financial results, highlighting a revenue of $6.2 million from FYARRO sales, reflecting an 80% increase year-over-year. The company is progressing with its PRECISION1 trial and expanding its pipeline to include programs in Endometrial Cancer and Neuroendocrine Tumors (NETs).

Aadi Bioscience reported total revenue of $5.9 million from FYARRO® sales in Q1 2023, with a net loss of $15.2 million. The company is progressing with the PRECISION 1 tumor agnostic trial and expects an interim analysis by the end of 2023. They believe they are operating from a position of strength with solid cash balances into 2025.

Aadi Bioscience announced its Q4 and full-year 2022 financial results, featuring $5.2 million in FYARRO net product sales for the quarter and a net loss of $13.9 million. The company highlighted the progress of the PRECISION 1 trial and a new collaboration with Mirati Therapeutics.

Aadi Bioscience announced financial results for the third quarter of 2022, featuring a 24% revenue increase in FYARRO sales compared to the second quarter and the completion of a $72.5 million PIPE financing, extending the company's cash runway into 2025. The company's PRECISION 1 trial is on track, with preliminary data expected in the first half of 2023.

Aadi Bioscience reported total revenue of $3.4 million for the second quarter of 2022, driven by FYARRO net product sales. The company continues to advance its PRECISION 1 trial and evaluate new clinical indications for nab-sirolimus.

Aadi Bioscience reported FYARRO net product sales of $2.3 million in the first quarter of 2022, following its launch in February. The company's cash and cash equivalents totaled $129.8 million as of March 31, 2022. Net loss for the quarter was $13.9 million.

Aadi Bioscience reported a net loss attributable to common stockholders of $16.0 million for the fourth quarter of 2021, compared to a net income of $7.8 million in the prior year quarter. As of December 31, 2021, cash and cash equivalents totaled $149.0 million. FYARRO was approved by the FDA on November 22, 2021, and launched in February 2022.

Aadi Bioscience reported a net loss attributable to common stockholders of $87.2 million for the third quarter of 2021, primarily driven by a non-cash impairment charge of $74.2 million. The company ended the quarter with $161.4 million in cash and cash equivalents, which is expected to fund operations into 2024.

Aerpio Pharmaceuticals reported a net loss of $4.4 million for the three months ended June 30, 2021. The company had $36.8 million in cash and cash equivalents as of June 30, 2021. Aerpio entered into a merger agreement with Aadi Bioscience, Inc. on May 16, 2021.